SCHEMBL2308459

SCHEMBL2308459

C[C@@H]1CN(c2c(CO)cc(C(=O)c3cnccn3)c(F)c2F)C[C@H](C)O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
NPC1 O15118 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
USP30 Q70CQ3 1/20 0.32
MAPT P10636 1/20 0.32
GSK3B P49841 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
MAPK1 P28482 1/20 0.31
WNT3A P56704 1/20 0.31
TSHR P16473 1/20 0.31
SCN9A Q15858 1/20 0.31
ALOX15 P16050 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
PIM3 Q86V86 1/20 0.31
PIM2 Q9P1W9 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2310229 0.86 SCN9A (0.40) KDM4EHTTNPC1TDP1MAPK1
SCHEMBL2312015 0.84 KDM4E (0.39) KDM4EHTTNPC1TDP1USP30
SCHEMBL2306874 0.81 LRRK2 (0.34) KDM4EHTTNPC1MAPK1SCN9A
SCHEMBL2509678 0.81 LRRK2 (0.34) KDM4EHTTNPC1MAPK1SCN9A
SCHEMBL2309430 0.80 KDM4E (0.39) KDM4EHTTNPC1USP30MAPT
SCHEMBL3069796 0.79 KDM4E (0.38) KDM4EHTTNPC1TDP1MAPT
SCHEMBL2309750 0.79 TSHR (0.38) KDM4EHTTNPC1MAPTTSHR
SCHEMBL5014295 0.78 TSHR (0.37) KDM4EHTTNPC1TDP1USP30
SCHEMBL2305888 0.78 ALDH1A1 (0.45) KDM4ENPC1TDP1MAPTMAPK1
SCHEMBL2307645 0.76 TSHR (0.36) KDM4EHTTNPC1USP30TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368266-A1 CHEMICAL COMPOUNDS 542 ENTASIS THERAPEUTICS INC. 2015-12-24 US disclosed
US-9040528-B2 Chemical compounds 542 ASTRAZENECA AB (SE) 2015-05-26 US disclosed
US-20140128371-A1 CHEMICAL COMPOUNDS 542 ASTRAZENECA AB (SE) 2014-05-08 US disclosed
US-8658641-B2 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections ASTRAZENECA AB (SE) 2014-02-25 US disclosed
US-20110245224-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2011-10-06 US disclosed
EP-2350077-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AstraZeneca AB (SE) 2011-08-03 EP disclosed
WO-2010043893-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368266-A1 CHEMICAL COMPOUNDS 542 MRPL21, CFTR, CYP3A43 KDM4E 4091/4885HTT 3817/4885NPC1 148/4885
US-20110245224-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS SDHB, SDHA, RORC KDM4E 4677/4885HTT 4044/4885NPC1 309/4885
US-20140128371-A1 CHEMICAL COMPOUNDS 542 MRPL21, CFTR, CYP3A43 KDM4E 4091/4885HTT 3817/4885NPC1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.